A Big Week for GLP-1 Drugs A Breakthrough Award, New Evidence in Parkinson's and Heart Disease Theres been no shortage of buzz about the GLP-1 family of drugs, but that was amplified in many ways this week
No significant difference in the change in whole-body composition was observed between the semaglutide + lifestyle counseling group [0.005 g/cm 2 (95% CI: 0.012 to 0.023)] and the lifestyle counseling alone group [0.009 g/cm 2 (95% CI: 0.009 to 0.03)]
Noureddin M, Rinella M, Taub R, et al
Estimation of serum true collagen type III formation (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort
Back Marso, SP, Daniels, GH, Brown-Frandsen, K, et al (28 July 2016) 'Liraglutide and cardiovascular outcomes in type 2 diabetes', New England Journal of Medicine , 375/4, 311-22
Some people notice reduced cravings within the first few days